Francisco Padilla, MD

Centro de Investigación en Cardiología y Metabolismo, Mexico

Disclosure(s): Amgen: Grant/Research Support, Personal fees; AstraZeneca: Grant/Research Support, Personal fees; Boehringer Ingelheim: Grant/Research Support, Personal fees; Ferrer: Grant/Research Support, Personal fees; Kowa: Grant/Research Support, Personal fees; Medix: Grant/Research Support, Personal fees; Merck Sharp and Dohme: Grant/Research Support, Personal fees; Novartis: Grant/Research Support, Personal fees; Pfizer: Grant/Research Support, Personal fees; Sanofi: Grant/Research Support, Personal fees; Servier: Grant/Research Support, Personal fees; Silanes: Grant/Research Support, Personal fees

Poster(s):

• 1160 - Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1918 - Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1924 - Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET